Johnson & Johnson (JNJ) is Palladium Partners LLC’s 3rd Largest Position
Palladium Partners LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 0.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 246,594 shares of the company’s stock after buying an additional 2,247 shares during the period. Johnson & Johnson comprises about 2.7% of Palladium Partners LLC’s holdings, making the stock its 3rd largest position. Palladium Partners LLC’s holdings in Johnson & Johnson were worth $29,912,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Americafirst Capital Management LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at about $101,000. Capital Asset Advisory Services LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at about $202,000. Terra Nova Asset Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter valued at about $243,000. Daiwa SB Investments Ltd. boosted its stake in shares of Johnson & Johnson by 8.4% in the second quarter. Daiwa SB Investments Ltd. now owns 2,970 shares of the company’s stock valued at $354,000 after buying an additional 230 shares in the last quarter. Finally, Pure Financial Advisors Inc. bought a new stake in shares of Johnson & Johnson during the second quarter valued at about $355,000. 65.32% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson (NYSE:JNJ) traded up 0.47% on Monday, reaching $119.80. 3,657,049 shares of the company’s stock traded hands. The stock has a market capitalization of $327.76 billion, a PE ratio of 22.33 and a beta of 0.62. The firm’s 50-day moving average is $118.85 and its 200 day moving average is $117.29. Johnson & Johnson has a 52-week low of $94.12 and a 52-week high of $126.07.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.06. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The firm earned $18.50 billion during the quarter, compared to the consensus estimate of $17.98 billion. Analysts forecast that Johnson & Johnson will post $6.69 EPS for the current year.
Several analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price objective for the company in a research note on Friday, August 5th. Jefferies Group restated a “hold” rating and set a $109.00 target price (up previously from $108.00) on shares of Johnson & Johnson in a report on Tuesday, June 14th. BMO Capital Markets restated an “outperform” rating and set a $132.00 target price on shares of Johnson & Johnson in a report on Wednesday, July 20th. Deutsche Bank AG restated a “hold” rating and set a $142.00 target price (up previously from $125.00) on shares of Johnson & Johnson in a report on Thursday, July 21st. Finally, Vetr upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $124.21 target price on the stock in a report on Monday, August 8th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $120.19.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the sale, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of the stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the sale, the vice president now directly owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.